Possible Roles of the AP-1 Site in the Cytosolic T3 Binding Protein Promoter and Insights into its Physiological Significance

Abstract

Cytosolic 3,5,3′-triiodo-l-thyronine-binding protein plays pivotal roles in the regulation of intracellular 3,5,3′-triiodo-l-thyronine concentration in vivo. The expression of the protein, which is identical to μ-crystallin, is regulated by various factors. To elucidate the mechanisms of its expression, we evaluated the promoter transactivity and insulin signaling via the AP-1 site in the promoter. The isolated 600 bp human and 1976 bp mouse 5′-flanking regions were cloned in a luciferase reporter plasmid. The luciferase activity was estimated in GH3, dRLh-84, HEK293, and insulin receptor-overexpressing CHO-IR cells. The effects of 12-O-tetradecanoylphorbol 13-acetate and insulin on μ-crystallin mRNA expression were evaluated in various cells. The region between −200 and the transcriptional start site was crucial for constitutive expression in μ-crystallin-expressing dRLh-84 cells. This region contained an AP-1 site. 12-O-Tetradecanoylphorbol 13-acetate increased the level of μ-crystallin mRNA expression in HEK 293 cells. The compound also increased luciferase activity through the promoter. Mutation in the AP1 site diminished the response to the compound. The promoter was also activated by insulin treatment in CHO-IR cells. Insulin treatment increased μ-crystallin mRNA expression in Raw264.7 cells, but decreased in HEK293, P19, and dRLH-84 cells. The expression of μ-crystallin was regulated through the AP-1 site in the promoter. The signals related to AP-1 activation, such as insulin signaling may have diverse effects on μ-crystallin mRNA expression.

Key words

TPA - thyroid hormone - binding protein - insulin - gene expression

• References

• 1 Cheng SY, Leonard JL, Davis PJ. Molecular aspects of thyroid hormone actions. Endocr Rev 2010; 31: 139-170
• 2 Salvatole D, Davis TF, Schlumberger M-J, Hay ID, Larsen PR. Thyroid physiology and diagnostic evaluation of patients with thyroid disorders. In: Melmed S, Polonsky KS, Larsen PR, Kronenberg HM. (eds.). Williams Textbook of Endocrinology. Philadelphia: Saunders; 2011: 327-361
• 3 Visser WE, Friesema EC, Visser TJ. Minireview: thyroid hormone transporters: the knowns and the unknowns. Mol Endocrinol 2011; 25: 1-14
• 4 Webb P, Phillips K, Baxter JD. Mechanisms of thyroid hormone action. In: Jameson JL, DeGroot LJ. (ed.). Endocrinology. Philadelphia: Saunders; 2010: 1423-1443
• 5 Mori J-I, Suzuki S, Kobayashi M, Inagaki T, Komatsu A, Takeda T, Miyamoto T, Ichikawa K, Hashizume K. Nicotinamide adenine dinucleotide phosphate-dependent cytosolic T3 binding protein as a regulator for T3-mediated transactivation. Endocrinology 2002; 143: 1538-1544
• 6 Vié MP, Evrard C, Osty J, Breton-Gilet A, Blanchet P, Pomérance M, Rouget P, Francon J, Blondeau JP. Purification, molecular cloning, and functional expression of the human nicodinamide-adenine dinucleotide phosphate-regulated thyroid hormone-binding protein. Mol Endocrinol 1997; 11: 1728-1736
• 7 Suzuki S, Suzuki N, Mori J-I, Oshima A, Usami S, Hashizume K. μ-crystallin as an intracellular 3,5,3′-triiodothyronine holder in vivo. Mol Endocrinol 2007; 21: 885-894
• 8 Suzuki S, Mori J, Kobayashi M, Inagaki T, Inaba H, Komatsu A, Yamashita K, Takeda T, Miyamoto T, Ichikawa K, Hashizume K. Cell-specific expression of NADPH-dependent cytosolic 3,5,3′-triiodo-l-thyronine-binding protein (p38CTBP). Eur J Endocrinol 2003; 148: 259-268
• 9 Suzuki S, Hashizume K, Ichikawa K, Takeda T. Ontogenesis of the high affinity NADPH-dependent cytosolic 3,5,3′-triiodo-l-thyronine-binding protein in rat. Endocrinology 1991; 129: 2571-2574
• 10 Suzuki S, Mori J, Hashizume K. μ-crystallin, a NADPH-dependent T3-binding protein in cytosol. Trends Endocrinol Metab 2007; 18: 286-289
• 11 Oshima A, Suzuki S, Takumi Y, Hashizume K, Abe S, Usami S. CRYM mutations cause deafness through thyroid hormone binding properties in the fibrocytes of the cochlea. J Med Genet 2006; 43: e25
• 12 Abe S, Katagiri T, Saito-Hisaminato A, Usami S, Inoue Y, Tsunoda T, Nakamura Y. Identification of CRYM as a candidate responsible for nonsyndromic deafness, through cDNA microarray analysis of human cochlear and vestibular tissues. Am J Hum Genet 2003; 72: 73-82
• 13 Arlotta P, Molyneaux BJ, Chen J, Inoue J, Kominami R, Macklis JD. Neuronal subtype-specific genes that control corticospinal motor neuron development in vivo. Neuron 2005; 45: 207-221
• 14 Imai H, Ohta K, Yoshida A, Suzuki S, Hashizume K, Usami S, Kikuchi T. μ-crystallin, new candidate protein in endotoxin-induced uveitis. Invest Ophthalmol Vis Sci 2010; 51: 3554-3559
• 15 Daoud H, Valdmanis PN, Gros-Louis F, Belzil V, Spiegelman D, Henrion E, Diallo O, Desjarlais A, Gauthier J, Camu W, Dion PA, Rouleau GA. Resequencing of 29 candidate genes in patients with familial and sporadic amyotrophic lateral sclerosis. Arch Neurol 2011; 68: 587-593
• 16 Segovia L, Horwitz J, Gasser R, Wistow G. Two roles for mu-crystallin: a lens structural protein in diurnal marsupials and a possible enzyme in mammalian retinas. Mol Vis 1997; 3: 9
• 17 Hallen A, Cooper AJ, Jamie JF, Haynes PA, Willows RD. Mammalian forebrain ketimine reductase identified as μ-crystallin: potential regulation by thyroid hormones. J Neurochem 2011; 42: 1397-1404
• 18 Suzuki S, Miyamoto T, Opsahl A, Sakurai A, DeGroot LJ. Two thyroid hormone response elements are present in the promoter of human thyroid hormone receptor beta 1. Mol Endocrinol 1994; 8: 305-314
• 19 Chen ZQ, Annilo T, Shulenin S, Dean M. Three ATP-binding cassette transporter genes, Abca14, Abca15, and Abca16, form a cluster or mouse Chromosome 7F3. Mamm Genome 2004; 15: 335-343
• 20 Ichikawa K, Miyamoto T, Kakizawa T, Suzuki S, Kaneko A, Mori J, Hara M, Kumagai M, Takeda T, Hashizume K. Mechanism of liver-selective thyromimetic activity of SK&F L-94901: evidence for the presence of a cell-type-specific nuclear iodothyronine transport process. J Endocrinol 2000; 165: 391-397
• 21 Hess J, Angel P, Schorpp-Kistner M. AP-1 subunits: quarrel and harmony among siblings. J Cell Sci 2004; 117: 5965-5973
• 22 Conejo R, Valverde AM, Benito M, Lorenzo M. Insulin produces myogenesis in C2C12 myoblasts by induction of NF-kappaB and downregulation of AP-1 activities. J Cell Physiol 2001; 186: 82-94
• 23 Yamauchi K, Pessin JE. Enhancement or inhibition of insulin signalling by insulin receptor substrate 1 is cell context dependent. Mol Cell Biol 1994; 14: 4427-4434
• 24 Hennessy E, O’Driscoll L. Molecular medicine of microRNAs: structure, function and implications for diabetes. Expert Rev Mol Med 2008; 10: e24
• 25 Woodcroft KJ, Hafner MS, Novak RF. Insulin signalling in the transcriptional and posttranscriptional regulation of Cyp2E1 expression. Hepatology 2002; 35: 263-273
• 26 Yelaturu CR, Deng X, Park EA, Raghow R, Elam MB. Insulin enhances the biogenesis of nuclar sterol regulatory element-binding protein (SREBP)-1c by posttranscriptional down-regulation of Insig-2A and its dissociation from SREBP cleavage-activating protein (SCAP)-SREBP-1c complex. J Biol Chem 2009; 284: 31726-31734
• 27 Herdegen T, Waetzig V. AP-1 proteins in the adult brain: facts and fiction about effectors of neuroprotection and neurodegeneration. Oncogene 2001; 20: 2424-2437